search
Back to results

Effects of Alkaline Phosphatase on Renal Function in Septic Patients

Primary Purpose

Severe, Septic, Shock

Status
Completed
Phase
Phase 2
Locations
Netherlands
Study Type
Interventional
Intervention
bolus injection, followed by a continuous infusion ( 24 h) (Alkaline phosphatase)
Sponsored by
Radboud University Medical Center
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Severe focused on measuring alkaline phosphatase, sepsis, kidney function

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Written informed consent
  • Proven or suspected Gram-negative bacterial infection
  • Two out of four Systemic Inflammatory Response Syndrome (SIRS) criteria existing for less than 24 h
  • Acute onset of end-organ dysfunction in the preceding 12 h

Exclusion Criteria:

  • Prior therapy with alkaline phosphatase
  • Known allergy for cow milk
  • Probable death within 24 h
  • Chronic renal failure requiring hemodialysis or peritoneal dialysis
  • Acute pancreatitis with no established source of infection
  • HIV seropositive
  • Pregnant or lactating
  • Confirmed Gram-positive or fungal sepsis
  • Treatment with immunosuppressants including high doses of glucocorticosteroids

Sites / Locations

  • Radboud University Medical Centre

Outcomes

Primary Outcome Measures

Biomarkers of kidney damage
kidney function
markers of inflammation

Secondary Outcome Measures

Full Information

First Posted
April 4, 2007
Last Updated
April 5, 2007
Sponsor
Radboud University Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT00457613
Brief Title
Effects of Alkaline Phosphatase on Renal Function in Septic Patients
Official Title
Effects of Alkaline Phosphatase on Renal Function in Patients With Severe Sepsis or Septic Shock.
Study Type
Interventional

2. Study Status

Record Verification Date
March 2006
Overall Recruitment Status
Completed
Study Start Date
November 2004 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
March 2006 (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Radboud University Medical Center

4. Oversight

5. Study Description

Brief Summary
Septic shock is the most common cause of death in patients requiring intensive care. The kidney is one of the first organs to fail, stressing the importance to search for clinical interventions that may protect the kidneys during sepsis. Alkaline phosphatase functions as a host defence molecule and is present in many cells and organs (e.g. intestine, placenta, liver, kidney and bone). Alkaline phosphatase has a dual mode of action. First, it binds to and, subsequently, dephosphorylates lipopolysaccharide (LPS). Second, the enzymatic reaction product monophosphoryl-LPS is a non-toxic substance for mammals which acts as a partial antagonist on the LPS receptor complex. In several animal studies, administration of alkaline phosphatase attenuates the inflammatory response and reduces mortality. It is unknown whether these results can be extrapolated to septic patients . We studied the effects of alkaline phosphatse administration on kidney damage and function in patients with severe sepsis or septic shock.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Severe, Septic, Shock
Keywords
alkaline phosphatase, sepsis, kidney function

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
15 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
bolus injection, followed by a continuous infusion ( 24 h) (Alkaline phosphatase)
Primary Outcome Measure Information:
Title
Biomarkers of kidney damage
Title
kidney function
Title
markers of inflammation

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Written informed consent Proven or suspected Gram-negative bacterial infection Two out of four Systemic Inflammatory Response Syndrome (SIRS) criteria existing for less than 24 h Acute onset of end-organ dysfunction in the preceding 12 h Exclusion Criteria: Prior therapy with alkaline phosphatase Known allergy for cow milk Probable death within 24 h Chronic renal failure requiring hemodialysis or peritoneal dialysis Acute pancreatitis with no established source of infection HIV seropositive Pregnant or lactating Confirmed Gram-positive or fungal sepsis Treatment with immunosuppressants including high doses of glucocorticosteroids
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Peter Pickkers, MD, PhD
Organizational Affiliation
Radboud University Medical Center
Official's Role
Study Director
Facility Information:
Facility Name
Radboud University Medical Centre
City
Nijmegen
State/Province
Gelderland
Country
Netherlands

12. IPD Sharing Statement

Learn more about this trial

Effects of Alkaline Phosphatase on Renal Function in Septic Patients

We'll reach out to this number within 24 hrs